<DOC>
	<DOCNO>NCT00518531</DOCNO>
	<brief_summary>The primary objective evaluate adherence subject subcutaneous ( SC ) 60 mg denosumab every 6 month ( Q6M ) treatment compare oral 70 mg alendronate week ( QW ) treatment end treatment period 1 ( 12 month ) .</brief_summary>
	<brief_title>Denosumab Adherence Preference Satisfaction Study</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Ambulatory postmenopausal woman base medical history &gt; = 55 year age start screen Screening bone mineral density ( BMD ) value ( g/cmÂ² ) , lumbar spine OR femoral neck OR total hip occur within specify range base particular scanner use . At least 2 lumbar vertebra must evaluable Dual Xray Absorptiometry ( DXA ) , least one hip must evaluable DXA Provide write informed consent study specific procedure perform . Any disorder compromise ability subject give write informed consent and/or comply study procedure Hyper hypothyroidism ; however , stable subject , investigator 's opinion , thyroid hormone replacement therapy allow Current hyper hypoparathyroidism Current hypo hyper calcemia base central laboratory reference range albuminadjusted serum calcium Rheumatoid arthritis , Paget 's disease , Cushing 's disease , hyperprolactinemia , cirrhosis liver Any metabolic bone disease , e.g . osteomalacia osteogenesis imperfecta , may interfere interpretation finding Any symptomatic vertebral fracture within 3 month prior screen Previous participation clinical trial denosumab Vitamin D deficiency [ 25 ( OH ) vitamin D level &lt; 20 ng/mL ( &lt; 49.9 nmol/L ) ] Contraindicated alendronate therapy ; contraindication alendronate therapy include : 1 . Abnormalities esophagus , delay esophageal emptying stricture achalasia . 2 . Inability stand sit upright least 30 minute . 3 . Hypersensitivity alendronate ( ALN ) constituent ALN tablet . Any known prior bisphosphonate use Currently enrol yet complete least 1 month since end investigational device drug trail ( ) , subject receive investigational agent ( ) .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>low bone mineral density</keyword>
	<keyword>alendronate</keyword>
	<keyword>denosumab</keyword>
	<keyword>adherence</keyword>
	<keyword>preference</keyword>
	<keyword>satisfaction</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>woman</keyword>
</DOC>